186 related articles for article (PubMed ID: 34732839)
21. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
22. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.
Hong YS; Kim SY; Lee JS; Nam BH; Kim KP; Kim JE; Park YS; Park JO; Baek JY; Kim TY; Lee KW; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
J Clin Oncol; 2019 Nov; 37(33):3111-3123. PubMed ID: 31593484
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
25. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
[TBL] [Abstract][Full Text] [Related]
26. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
27. [Immune-Related Factors as Prognostic Markers for Resectable Colorectal Cancer].
Tomochika S; Kuwahara T; Suzuki N; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2021 Mar; 48(3):325-330. PubMed ID: 33790150
[TBL] [Abstract][Full Text] [Related]
28. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
30. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
[TBL] [Abstract][Full Text] [Related]
31. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
[TBL] [Abstract][Full Text] [Related]
33. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
BMC Cancer; 2019 Mar; 19(1):255. PubMed ID: 30898102
[TBL] [Abstract][Full Text] [Related]
34.
Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
[TBL] [Abstract][Full Text] [Related]
35. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
36. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
37. CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
Nakagami Y; Hazama S; Suzuki N; Yoshida S; Tomochika S; Matsui H; Shindo Y; Tokumitsu Y; Matsukuma S; Watanabe Y; Iida M; Tsunedomi R; Takeda S; Fujita T; Kawakami Y; Ogihara H; Hamamoto Y; Ioka T; Tanabe T; Ueno T; Nagano H
BMC Cancer; 2022 Oct; 22(1):1071. PubMed ID: 36253752
[TBL] [Abstract][Full Text] [Related]
38. Combinatory statuses of tumor stromal percentage and tumor infiltrating lymphocytes as prognostic factors in stage III colorectal cancers.
Jin HY; Yoo SY; Lee JA; Wen X; Kim Y; Park HE; Kwak Y; Cho NY; Bae JM; Kim JH; Lee HS; Kang GH
J Gastroenterol Hepatol; 2022 Mar; 37(3):551-557. PubMed ID: 35018665
[TBL] [Abstract][Full Text] [Related]
39. A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer.
Li S; Sun S; Sun H; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Wang W; Li Z; Ma Y; Xue Y; Zhao Y
Int Immunopharmacol; 2021 Jul; 96():107589. PubMed ID: 34162126
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
